Page 35 - Practice Guidelines News Today

/PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) hosted a policy summit to examine practice changes and trends in legislative and...

National Comprehensive Cancer Networks #NCCNPolicy Summit, featuring White House Moonshot Coordinator and representatives from CDC, NCI, and USPSTF, examines

15.09.2022 - SURREY, BC / ACCESSWIRE / September 15, 2022 / Condor Gold (AIM:CNR; TSX:COG) is pleased to announce the results and details of a Feasibility Study, sometimes referred to as a Bankable Feasibility Study (2022 FS) on the La India open pit. The 2022 ...

HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial

An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type PLYMOUTH MEETING, Pa., Sept. 13, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network(NCCN) has published new NCCN Guidelines for Patients: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin l...

An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type PLYMOUTH MEETING, Pa., Sept. 13, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin...

An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type PLYMOUTH MEETING, Pa., Sept. 13, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network(NCCN) has published new NCCN Guidelines for Patients: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin l...

New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to

According to Mayo Clinic Comprehensive Cancer Center researchers, metabolic imaging (FDG-PET) in combination with traditional treatment response assessment methods can provide clinicians with critical information they need to guide therapy for pancreatic cancer patients. Increasingly impactful nature of research in JNCCN reflected in new high for the journal's Impact Factor, now 12.693. PLYMOUTH MEETING, Pa., Sept. 9, 2022 /PRNewswire/ -- New research in the September 2022 issue of JNCCN-Jou...

Landmark 5-year follow-up of PAOLA-1 Phase III trial demonstrated LYNPARZA plus bevacizumab meaningfully extended survival with 65.5% of HRD-positive patients surviving 5 years vs. 48.4% treated with